Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Pathogenesis and Treatment of Diabetic Cardiomyopathy
share announcement

Pathogenesis and Treatment of Diabetic Cardiomyopathy

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1417

Special Issue Editor

Dr. Óscar Lorenzo

E-Mail Website
Guest Editor
IIS-Fundación Jiménez Diaz, Universidad Autónoma de Madrid, Madrid, Spain.
Interests: diabetic cardiomyopathy; molecular mechanisms; risk factors; diagnosis; therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetic cardiomyopathy refers to cardiac alterations induced by the diabetic milieu. Although these injuries are independent of the vascular damages associated with diabetes, they frequently coexist, leading to adverse cardiovascular abnormalities that are considered as the major causes of death in this population. Due to the complexity of this disease, the underlying mechanisms of action has not been fully unveiled yet, making it difficult to discover efficient treatment pathways for patients. Hence, research on the potential activated pathways of the diabetic heart and on the impact of new anti-hyperglycemic/lipidemic drugs on the myocardium is encouraged to develop new therapeutic strategies.

Dr. Óscar Lorenzo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetic cardiomyopathy
  • molecular mechanisms
  • risk factors
  • diagnosis
  • therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 2394 KiB  
Review
Diabetic Cardiomyopathy—From Basics through Diagnosis to Treatment
by Ewa Radzioch, Bartłomiej Dąbek, Marta Balcerczyk-Lis, Weronika Frąk, Piotr Fularski, Ewelina Młynarska, Jacek Rysz and Beata Franczyk
Biomedicines 2024, 12(4), 765; https://doi.org/10.3390/biomedicines12040765 - 29 Mar 2024
Viewed by 587
Abstract
Diabetic cardiomyopathy (DCM) is the development of myocardial dysfunction in patients with diabetes despite the absence of comorbidities such as hypertension, atherosclerosis or valvular defect. The cardiovascular complications of poorly controlled diabetes are very well illustrated by the U.K. Prospective Diabetes Study (UKPDS), [...] Read more.
Diabetic cardiomyopathy (DCM) is the development of myocardial dysfunction in patients with diabetes despite the absence of comorbidities such as hypertension, atherosclerosis or valvular defect. The cardiovascular complications of poorly controlled diabetes are very well illustrated by the U.K. Prospective Diabetes Study (UKPDS), which showed a clear association between increasing levels of glycated hemoglobin and the development of heart failure (HF). The incidence of HF in patients with diabetes is projected to increase significantly, which is why its proper diagnosis and treatment is so important. Providing appropriate therapy focusing on antidiabetic and hypolipemic treatment with the consideration of pharmacotherapy for heart failure reduces the risk of CMD and reduces the incidence of cardiovascular complications. Health-promoting changes made by patients such as a low-carbohydrate diet, regular exercise and weight reduction also appear to be important in achieving appropriate outcomes. New hope for the development of therapies for DCM is offered by novel methods using stem cells and miRNA, which, however, require more thorough research to confirm their efficacy. Full article
(This article belongs to the Special Issue Pathogenesis and Treatment of Diabetic Cardiomyopathy)
►▼ Show Figures

Figure 1

16 pages, 1579 KiB  
Review
Interplay between Senescence and Macrophages in Diabetic Cardiomyopathy: A Review of the Potential Role of GDF-15 and Klotho
by Ghada M. Almohaimeed, Asma S. Alonazi, Anfal F. Bin Dayel, Tahani K. Alshammari, Hanan K. Alghibiwi, Maha A. Alamin, Ahmad R. Almotairi and Nouf M. Alrasheed
Biomedicines 2024, 12(4), 759; https://doi.org/10.3390/biomedicines12040759 - 29 Mar 2024
Viewed by 479
Abstract
Type 2 diabetes mellitus (T2DM) is a critical health problem, with 700 million diagnoses expected worldwide by 2045. Uncontrolled high blood glucose levels can lead to serious complications, including diabetic cardiomyopathy (DCM). Diabetes induces cardiovascular aging and inflammation, increasing cardiomyopathy risk. DCM is [...] Read more.
Type 2 diabetes mellitus (T2DM) is a critical health problem, with 700 million diagnoses expected worldwide by 2045. Uncontrolled high blood glucose levels can lead to serious complications, including diabetic cardiomyopathy (DCM). Diabetes induces cardiovascular aging and inflammation, increasing cardiomyopathy risk. DCM is characterized by structural and functional abnormalities in the heart. Growing evidence suggests that cellular senescence and macrophage-mediated inflammation participate in the pathogenesis and progression of DCM. Evidence indicates that growth differentiation factor-15 (GDF-15), a protein that belongs to the transforming growth factor-beta (TGF-β) superfamily, is associated with age-related diseases and exerts an anti-inflammatory role in various disease models. Although further evidence suggests that GDF-15 can preserve Klotho, a transmembrane antiaging protein, emerging research has elucidated the potential involvement of GDF-15 and Klotho in the interplay between macrophages-induced inflammation and cellular senescence in the context of DCM. This review explores the intricate relationship between senescence and macrophages in DCM while highlighting the possible contributions of GDF-15 and Klotho. Full article
(This article belongs to the Special Issue Pathogenesis and Treatment of Diabetic Cardiomyopathy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop